Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

American Journal of Hematology

Volumn 85, Issue 10, 2010, Pages 757-759

  Dispenzieri, Angela ^a   Dingli, David ^a   Kumar, Shaji K ^a   Rajkumar, S Vincent ^a   Lacy, Martha Q ^a   Hayman, Suzanne ^a   Buadi, Frances ^a   Zeldenrust, Stephen ^a   Leung, Nelson ^a   Detweiler Short, Kristen ^a   Lust, John A ^a   Russell, Stephen J ^a   Kyle, Robert A ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOMODULATING AGENT; TROPONIN T; AMYLOID; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOLOGIC FACTOR; LENALIDOMIDE; MELPHALAN; PEPTIDE FRAGMENT; POMALIDOMIDE; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); THALIDOMIDE;

AMYLOIDOSIS; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE MARKER; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID RETENTION; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; HEART FAILURE; MULTIMODALITY CANCER THERAPY; PATIENT DROPOUTS; STATISTICS AND NUMERICAL DATA; STEM CELL TRANSPLANTATION;

AMYLOID; AMYLOIDOSIS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOLOGIC FACTORS; MELPHALAN; NATRIURETIC PEPTIDE, BRAIN; PATIENT DROPOUTS; PEPTIDE FRAGMENTS; STEM CELL TRANSPLANTATION; THALIDOMIDE; TROPONIN T;

EID: 77957690324     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21822     Document Type: Article

References (15)

1. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-470.
2. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 2007;109:492-496.
3. Dispenzieri A, Lacy M, Zeldenrust S, et al. Cardiac biomarkers predict for ability to tolerate and complete therapy with lenalidomide {+/-} dexamathosone in AL amyloidosis. ASH Annu Meet Abstr 2006;108:130.
4. Dispenzieri A, Lacy M, Zeldenrust SR, et al. Long term follow-up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone. Blood (ASH Annu Meet Abstr) 2008;112:1737.
5. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787-1789.
6. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-3757.
7. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-3858.
8. Wechalekar A, Merlini G, Gillmore JD, et al. Role of NT-ProBNP to assess the adequacy of treatment response in AL amyloidosis. Blood (ASH Annu Meet Abstr) 2008;112:1689.
9. Gibbs SDJ, De Cruz M, Sattianayagam PT, et al. Transient post chemotherapy rise in NT Pro-BNP in AL Amyloidosis : Implications for organ response assessment. Blood (ASH Annu Meet Abstr) 2009;114:1791.
10. Madan S, Kumar S, Dispenzieri A, et al. Outcomes with high dose therapy and peripheral blood stem cell transplantation for light chain (AL) amyloidosis with cardiac involvement. ASH Annu Meet Abstr 2009;114:534.
11. Dispenzieri A, Gertz MA, Hayman SR, et al. A Pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients. Blood (ASH Annu Meet Abstr) 2009;114:3854.
12. Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10:257-261.
13. Kumar S, Hayman SR, Buadi F, et al. A Phase II Trial of Lenalidomide, Cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis. Blood (ASH Annu Meet Abstr) 2009;114:3853.
14. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-328.
15. Palladini G, Russo P, Bragotti LZ, et al. A Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) in Previously Treated Patients with AL Amyloidosis. ASH Annu Meet Abstr 2009;114:2863.